Onkológia 6/2024

Elderly patient with adjuvant treatment with atezolizumab for pleomorphic lung cancer - a case report

Introduction: Adjuvant chemotherapy followed by atezolizumab is the standard treatment for completely resected NSCLC (non-small cell lung cancer) in stages II - IIIA, irrespective of the histological subtype.Pleomorphic carcinoma is a rare form of NSCLC, occurring in approximately 1% of all cases. Case report: We present a case of pleomorphic NSCLC in a 75-year-old male patient with a performance status of 0. The patient underwent surgery, followed by adjuvant chemotherapy and atezolizumab. He received four cycles of chemotherapy supported by pegfilgrastim, followed by 16 cycles of atezolizumab. Notably, there were no unexpected or serious adverse events during the treatment. We also discuss the relevant literature that supports this treatment approach. Conclusion: Adjuvant chemotherapy followed by atezolizumab is a feasible option for older patients with rare subtypes of NSCLC, such as pleomorphic carcinoma.

Keywords: non-small cell lung cancer, pleomorphic cancer, elderly patient, adjuvant therapy